Starling Oncology, Inc. Federal Income Tax Expense (Benefit), Continuing Operations
Starling Oncology, Inc. (DFPH) reported Federal Income Tax Expense (Benefit), Continuing Operations of -$131.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-03-12
- Starling Oncology, Inc. federal income tax expense (benefit), continuing operations for fiscal 2025 was -$131.00K.
- Starling Oncology, Inc. federal income tax expense (benefit), continuing operations for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Starling Oncology, Inc. federal income tax expense (benefit), continuing operations for fiscal 2023 was $85.00K.
- Starling Oncology, Inc. federal income tax expense (benefit), continuing operations for fiscal 2022 was -$135.00K.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2025-12-31 | -$131.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2023-12-31 | $85.00K 10-K · filed 2025-03-26 |
| 2022-12-31 | -$135.00K 10-K · filed 2024-03-28 |
| 2021-12-31 | -$1.08M 10-K · filed 2023-03-16 |
| 2020-12-31 | -$97.00K 10-K · filed 2022-03-11 |